Deferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload in patients receiving long term blood transfusions.
Synonyms
Deferasiroxum
Deferasirox
Brand Names
Apo-deferasirox (type J)
Deferasirox Mylan
Teva-deferasirox
Jadenu
Sandoz Deferasirox
Deferasirox Accord
PMS-deferasirox
Exjade
Taro-deferasirox
Apo-deferasirox
Deferasirox (type J)
Sandoz Deferasirox (type J)
Taro-deferasirox (type J)
Deferasirox Oral Granules
Deferasirox
PMS-deferasirox (type J)
Deferasorox
Deferasirox oral
Teva-deferasirox (type J)
Auro-deferasirox (type J)
Indication
For the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.
Categories
Acids, Carbocyclic
Benzene Derivatives
Benzoates
Chelating Agents
Compounds used in a research, industrial, or household setting
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682